+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Schizophrenia Drugs Market - Growth, Trends, and Forecasts (2020-2025)

  • ID: 4787478
  • Report
  • May 2020
  • Region: Global
  • 114 pages
  • Mordor Intelligence

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Alkermes Plc
  • Allergan Plc
  • AstraZeneca
  • Eli Lilly and Company
  • Johnson & Johnson
  • Pfizer Inc.
  • MORE
Subtle changes in cognition and social relationships are expected to precede the actual diagnosis, often by years. According to the World Health Organization 2019 report, the disease affects 20 million people worldwide. Furthermore, this number is likely to continue to increase, along with the growth in the aging population. The increase in the number of patients taking treatment and rising demand for improved healthcare infrastructure are expected to drive the market. In recent years, the government in several countries have collaborated well with many hospitals across nations to give moe protection to people from schizophrenia. The rising burden of the disease and the increasing need to manage it effectively is driving the growth of the market studied.

Key Market Trends

The Second-generation Antipsychotics Sub-segment is Expected to record the Better Growth Over the Forecast Period

The usual first-line treatment for schizophrenia is antipsychotic medication. One of the commonly preferred medications is risperidone, which is also known as a second-generation antipsychotic (SGA) or atypical antipsychotic. Risperidone rebalances dopamine and serotonin to improve thinking, mood, and behavior. It is expected to help in curing some or all of the symptoms of schizophrenia. Moreover, in the United States the Food and Drug Administration (FDA) approved for acute treatment of manic or mixed episodes of bipolar disorder, maintenance (long-term) treatment of bipolar disorder (Risperdal Consta® only), and irritability associated with autistic disorders. There are several second-generation drugs available in the market, which are commonly proposed by doctors/physicians. Continuous support by the government to private and public healthcare companies also boosts the growth of companies in this segment. Therefore, considering the aforementioned reasons, the market for second-generation antipsychotics is likely to grow steadily over the forecast period.

The North American is Expected to Dominate the Market Over the Forecast Period

The North American region is expected to dominate the market studied over the forecast period. In the North American region, the United States accounted for the largest market share, as a major section of the population is approaching such medications therapies, primarily due to hectic lifestyles. Moreover, the country offers highly advanced medical care, for early treatment capabilities, along with the involvement of government in increasing healthcare expenditure. This is driving the growth of the market studied.

Competitive Landscape

The Schizophrenia Drugs market is competitive and consists of major and small players. In terms of market share, the major players currently dominate the market. Some of the major market players include Alkermes Plc, Bristol-Myers Squibb, Eli Lilly and Company, Johnson & Johnson, and Allergan Plc, among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alkermes Plc
  • Allergan Plc
  • AstraZeneca
  • Eli Lilly and Company
  • Johnson & Johnson
  • Pfizer Inc.
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Schizophrenia and Associated Disorders
4.2.2 Increase in Focus of Governments and Health Care Organizations on Mental Health
4.2.3 Increasing Investments in R&D
4.3 Market Restraints
4.3.1 Increase in Cases of Addiction Associated with these Drugs
4.3.2 Patent Expiry of Major Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Therapeutic Class
5.1.1 Second-generation Antipsychotics
5.1.2 Third-generation Antipsychotics
5.1.3 Other Therapeutic Classes
5.2 By Treatment
5.2.1 Oral
5.2.2 Injectables
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Alkermes Plc
6.1.2 Allergan Plc
6.1.3 AstraZeneca
6.1.4 Eli Lilly and Company
6.1.5 Johnson & Johnson
6.1.6 Pfizer Inc.
6.1.7 Sumitomo Dainippon Pharma
6.1.8 Vanda Pharmaceuticals
6.1.9 Otsuka America Pharmaceutical, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Alkermes Plc
  • Allergan Plc
  • AstraZeneca
  • Eli Lilly and Company
  • Johnson & Johnson
  • Pfizer Inc.
  • Sumitomo Dainippon Pharma
  • Vanda Pharmaceuticals
  • Otsuka America Pharmaceutical, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll